High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

被引:38
|
作者
Alba, Emilio [1 ]
Lluch, Ana [2 ]
Ribelles, Nuria [1 ]
Anton-Torres, Antonio [3 ]
Sanchez-Rovira, Pedro [4 ]
Albanell, Joan [5 ,6 ]
Calvo, Lourdes [7 ]
Lopez Garcia-Asenjo, Jose Antonio [8 ]
Palacios, Jose [9 ]
Ignacio Chacon, Jose [10 ]
Ruiz, Amparo [11 ]
De la Haba-Rodriguez, Juan [12 ]
Segui-Palmer, Miguel A. [13 ]
Cirauqui, Beatriz [14 ]
Margeli, Mireia [14 ]
Plazaola, Arrate [15 ]
Barnadas, Agusti [16 ]
Casas, Maribel [17 ]
Caballero, Rosalia [17 ]
Carrasco, Eva [17 ]
Rojo, Federico [18 ]
机构
[1] Virgen de la Victoria Univ Hosp, Malaga, Spain
[2] Valencia Univ Hosp, Valencia, Spain
[3] Miguel Servet Univ Hosp, Zaragoza, Spain
[4] Jaen Hosp Complex, Jaen, Spain
[5] Inst Hosp del Mar Invest Med, Hosp del Mar, Med Res Inst, Barcelona, Spain
[6] Pompeu Fabra Univ, Barcelona, Spain
[7] A Coruna Univ Hosp Complex, La Coruna, Spain
[8] San Carlos Univ Hospial, Madrid, Spain
[9] Ramon y Cajal Univ Hosp, Madrid, Spain
[10] Virgen de la Salud Hosp, Toledo, Spain
[11] Valencian Inst Oncol, Valencia, Spain
[12] Reina Sofia Hosp Complex, Biomed Res Inst, Cordoba, Spain
[13] Parc Tauli Hlth Corp, Barcelona, Spain
[14] Germans Trias & Pujol Univ Hosp, Barcelona, Spain
[15] Onkologikoa, Donostia San Sebastian, Spain
[16] Santa Creu & St Pau Hosp, Barcelona, Spain
[17] GEICAM Spanish Breast Canc Res Grp, Madrid, Spain
[18] Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
来源
ONCOLOGIST | 2016年 / 21卷 / 02期
关键词
Ki67; Breast cancer; Neoadjuvant chemotherapy; Chemosensitivity; Predictive factor; PREOPERATIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; INTERNATIONAL KI67; ESTROGEN-RECEPTOR; AMERICAN SOCIETY; KI-67; RECOMMENDATIONS; RECURRENCE; EXPRESSION; SURVIVAL;
D O I
10.1634/theoncologist.2015-0312
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a predictor of response to chemotherapy is still controversial. Patients and Methods. We analyzed 262 patients with centralized basal Ki67 immunohistochemical evaluation derived from 4 GEICAM(Spanish Breast Cancer Group) clinical trials of neoadjuvant chemotherapy for breast cancer. The objective was to identify the optimal threshold for Ki67 using the receiver-operating characteristic curve method to maximize its predictive value for chemotherapy benefit. We also evaluated the predictive role of the defined Ki67 cutoffs for molecular subtypes defined by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). Results. A basal Ki67 cutpoint of 50% predicted pathological complete response (pCR). Patients with Ki67>50% achieved a pCR rate of 40% (36 of 91) versus a pCR rate of 19% in patients with Ki67 <= 50% (33 of 171) (p = .0004). Ki67 predictive value was especially relevant in ER-HER2- and ER-HER2+ patients (pCR rates of 42% and 64%, respectively, in patients with Ki67>50% versus 15% and 45%, respectively, in patients with Ki67 <= 50%; p = .0337 and .3238, respectively). Both multivariate analyses confirmed the independent predictive value of the Ki67 cutpoint of 50%. Conclusion. Basal Ki67 proliferation index >50% should be considered an independent predictive factor for pCR reached after neoadjuvant chemotherapy, suggesting that cell proliferation is a phenomenon closely related to chemosensitivity. These findings could help to identify a group of patients with a potentially favorable long-term prognosis.
引用
收藏
页码:150 / 155
页数:6
相关论文
共 50 条
  • [41] In-breast pathologic complete response (pCR) following neoadjuvant chemotherapy predicts nodal pCR in early stage breast cancer
    Shamseddine, Achraf
    Flynn, Jessica
    Zhang, Zhigang
    Morrow, Monica
    Mueller, Boris
    Gillespie, Erin
    Khan, Atif
    McCormick, Beryl
    Cahlon, Oren
    Powell, Simon
    Barrio, Andrea
    Braunstein, Lior Z.
    CANCER RESEARCH, 2020, 80 (04)
  • [42] GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
    Miyake, Tomohiro
    Nakayama, Takahiro
    Naoi, Yasuto
    Yamamoto, Noriaki
    Otani, Yoko
    Kim, Seung J.
    Shimazu, Kenzo
    Shimomura, Atsushi
    Maruyama, Naomi
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    CANCER SCIENCE, 2012, 103 (05): : 913 - 920
  • [43] Early changes of platelet-lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer
    Dan, Jiaqiang
    Tan, Jingya
    Huang, Junhua
    Yuan, Zhiying
    Guo, Yao
    MOLECULAR AND CLINICAL ONCOLOGY, 2023, 19 (05)
  • [44] Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer
    Hayashi, Yuji
    Takei, Hiroyuki
    Nozu, Satoshi
    Tochigi, Yoshihiro
    Ichikawa, Akihiro
    Kobayashi, Naoki
    Kurosumi, Masafumi
    Inoue, Kenichi
    Yoshida, Takashi
    Nagai, Shigenori E.
    Oba, Hanako
    Tabei, Toshio
    Horiguchi, Jun
    Takeyoshi, Izumi
    ONCOLOGY LETTERS, 2013, 5 (01) : 83 - 89
  • [45] Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy
    Jarzab, Michal
    Kowal, Monika
    Bal, Wieslaw
    Oczko-Wojciechowska, Malgorzata
    Rembak-Szynkiewicz, Justyna
    Kowalska, Malgorzata
    Stobiecka, Ewa
    Chmielik, Ewa
    Tyszkiewicz, Tomasz
    Kaszuba, Malgorzata
    Nowicka, Elzbieta
    Lange, Barbara
    Czarniecka, Agnieszka
    Krajewska, Jolanta
    Dyla, Alicja
    Dobrut, Miroslaw
    Lange, Dariusz
    Jarzab, Barbara
    Bobek-Billewicz, Barbara
    Tarnawski, Rafal
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2016, 54 (04) : 202 - 209
  • [46] Factors predicting complete pathological response to neoadjuvant chemotherapy in breast carcinoma
    Belhadj, O.
    Boudaouara, O.
    Ben Makhlouf, W.
    Triki, M.
    Zghal, M.
    Ayadi, L.
    Boudawara, T. Sellami
    Ben Kridis, W.
    VIRCHOWS ARCHIV, 2024, 485 : S188 - S188
  • [47] Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
    Zhao, Fangyuan
    Miyashita, Minoru
    Hattori, Masaya
    Yoshimatsu, Toshio
    Howard, Frederick
    Kaneva, Kristiyana
    Jones, Ryan
    Bell, Joshua S. K.
    Fleming, Gini F.
    Jaskowiak, Nora
    Nanda, Rita
    Zheng, Yonglan
    Huo, Dezheng
    Olopade, Olufunmilayo I.
    JAMA NETWORK OPEN, 2023, 6 (03) : E233329
  • [48] Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Combining Both Clinicopathological and Imaging Indicators
    Wang, Haoqi
    Lu, Yuyang
    Li, Yilun
    Li, Sainan
    Zhang, Xi
    Geng, Cuizhi
    CURRENT PROBLEMS IN CANCER, 2022, 46 (06)
  • [49] Predictive biomarkers for pathological complete response in early-stage triple negative breast cancer following neoadjuvant chemotherapy
    Polho, Gabriel Berlingieri
    Testa, Laura
    Barroso-Sousa, Romualdo
    Bonadio, Renata Colombo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Predictors of Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Johnson, Jeffrey
    Barmparas, Galinos
    Chung, Alice
    Giuliano, Armando
    Amersi, Farin
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : 86 - 87